Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $47,442.50 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $27.11, for a total transaction of $47,442.50. Following the completion of the transaction, the insider now owns 6,781 shares of the company’s stock, valued at $183,832.91. The sale was disclosed in a filing with the SEC, which is available at this link.

Scott Bizily also recently made the following trade(s):

• On Thursday, July 11th, Scott Bizily sold 1,996 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $49,900.00.
• On Monday, July 1st, Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $21.36, for a total transaction of $90,737.28.
• On Thursday, May 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $25.45, for a total transaction of $44,537.50.

4D Molecular Therapeutics Stock Down 4.9 %

Shares of FDMT stock opened at $14.40 on Friday. The company has a 50 day moving average price of $23.36 and a 200-day moving average price of $24.95. 4D Molecular Therapeutics, Inc. has a 52 week low of $9.44 and a 52 week high of $36.25. The firm has a market capitalization of $744.48 million, a PE ratio of -5.90 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.07. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.44 million. Analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Barclays assumed coverage on shares of 4D Molecular Therapeutics in a research note on Monday, April 15th. They issued an “overweight” rating for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday, June 26th. Jefferies Financial Group increased their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday. Finally, BMO Capital Markets cut their price objective on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Buy” and an average target price of $43.63.

Institutional Trading of 4D Molecular Therapeutics

A number of large investors have recently made changes to their positions in the stock. Daiwa Securities Group Inc. grew its stake in shares of 4D Molecular Therapeutics by 23.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company’s stock worth $119,000 after acquiring an additional 1,110 shares during the period. Price T Rowe Associates Inc. MD grew its position in 4D Molecular Therapeutics by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,952 shares of the company’s stock valued at $764,000 after buying an additional 1,356 shares during the period. Bfsg LLC bought a new stake in 4D Molecular Therapeutics during the fourth quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. grew its position in 4D Molecular Therapeutics by 14.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,612 shares of the company’s stock valued at $438,000 after buying an additional 2,700 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in 4D Molecular Therapeutics by 702.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after buying an additional 3,026 shares during the period. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.